ライフサイエンスコーパス: IPV

1 IPV induced small but significant decreases in a composi

2 IPV-based protection alone might not provide sufficient

3 IPV-bOPV schedules resulted in almost a 0.3 log reductio

4 IPV-immunized mice were protected against WPV1-induced p

5 IPV-related firearm laws (predictor) and annual, state-s

6 INTERPRETATION: The lowest dose (1/10 IPV-Al) of the vaccine performed well both after two and

7 5 to receive 1/5 IPV-Al, 204 to receive 1/10 IPV-Al, and 206 to receive IPV.

8 type 2), and 98.5% (n=202, type 3); and 1/10 IPV-Al: 98.5% (n=201, type 1), 94.6% (n=193, type 2), an

9 e [1/5 IPV-Al], ten-times reduced dose [1/10 IPV-Al], or IPV) intramuscularly in the thigh at 6, 10,

10 , the Nanopatch, delivered monovalent type 2 IPV (IPV2) vaccine to the skin.

11 ded programme of immunisation schedule): 1/3 IPV-Al 98.5% (n=202, type 1), 97.6% (n=200; type 2), and

12 s; 205 were randomly assigned to receive 1/3 IPV-Al, 205 to receive 1/5 IPV-Al, 204 to receive 1/10 I

13 formulations (three-times reduced dose [1/3 IPV-Al], five-times reduced dose [1/5 IPV-Al], ten-times

14 ed to receive 1/3 IPV-Al, 205 to receive 1/5 IPV-Al, 204 to receive 1/10 IPV-Al, and 206 to receive I

15 200; type 2), and 99.5% (n=204, type 3); 1/5 IPV-Al: 99.5% (n=204, type 1), 96.1% (n=197, type 2), an

16 e [1/3 IPV-Al], five-times reduced dose [1/5 IPV-Al], ten-times reduced dose [1/10 IPV-Al], or IPV) i

17 Knowledge about IPV was high among vaccinators (94%).

18 which limited countries' abilities to access IPV in a timely manner, 105 of 126 countries using OPV o

19 During 2013-2015, 85 countries added IPV to their immunization schedules, 46 (55%) of which a

20 In addition, IPV does not remain stable over time at elevated tempera

21 IPV, by June all LGAs had HFs administering IPV and by July, 91% of the HFs in Kano reported adminis

22 f LGAs had at least 20% of HFs administering IPV, by June all LGAs had HFs administering IPV and by J

23 1% of the HFs in Kano reported administering IPV.

24 One or two doses of bOPV after IPV boosted intestinal immunity for poliovirus type 2, s

25 We aimed to analyse adverse events after IPV administration reported to the US Vaccine Adverse Ev

26 s in this assessment of adverse events after IPV.

27 Sudden infant death syndrome reports after IPV were consistent with reporting patterns for other va

28 rent IPV-bOPV schedules compared with an all-IPV schedule in infants.

29 ontaining IPV and bOPV, compared with an all-IPV schedule, and proportions of infants with protective

30 V-containing schedules compared with the all-IPV schedule for seroconversion (within a 10% margin) an

31 V-containing schedules compared with the all-IPV schedule, with no significant differences between gr

32 s remained elevated 6 and 11 months after an IPV boost, although at a lower level than reported at 1

33 IPV/OPV schedule instead of switching to an IPV-only schedule in 2005 would have kept population imm

34 onversion rate difference between IPV-Al and IPV was greater than -10%.

35 of two schedules of bivalent OPV (bOPV) and IPV and challenge with monovalent type 2 OPV, and stools

36 In the IPV-bOPV-bOPV, IPV-IPV-bOPV, and IPV-IPV-IPV groups, respectively, the proportions of chi

37 In the IPV-bOPV-bOPV, IPV-IPV-bOPV, and IPV-IPV-IPV groups, respectively, the proportions of chi

38 irus in the IPV-bOPV-bOPV, IPV-IPV-bOPV, and IPV-IPV-IPV groups, respectively, were 130 (77.4%) of 16

39 here are biosafety concerns for both OPV and IPV.

40 rrhea was not different between the tOPV and IPV groups (P = .18), the number of days with diarrhea (

41 ne to 12 weeks, the number of women with any IPV in the past week decreased from 57% (134 of 237) in

42 ber of administrations of a vaccine, such as IPV, this technology can serve as a tool to aid in the e

43 he aim of estimating the association between IPV and depression symptom severity.

44 f the seroconversion rate difference between IPV-Al and IPV was greater than -10%.

45 In the IPV-bOPV-bOPV, IPV-IPV-bOPV, and IPV-IPV-IPV groups, respectively, the

46 In the IPV-bOPV-bOPV, IPV-IPV-bOPV, and IPV-IPV-IPV groups, respectively, the

47 g to type 2 poliovirus in the IPV-bOPV-bOPV, IPV-IPV-bOPV, and IPV-IPV-IPV groups, respectively, were

48 f three sequential schedules: IPV-bOPV-bOPV, IPV-IPV-bOPV, or IPV-IPV-IPV.

49 ective was to assess the superiority of bOPV-IPV schedules over bOPV alone, as assessed by the primar

50 <0.0001) and 53 of 87 infants receiving bOPV-IPV (p<0.0001).

51 (tOPV at 6, 10, and 14 weeks), and the bOPV-IPV group (bOPV at 6, 10, and 14 weeks plus IPV at 14 we

52 ered in the Western Pacific Region with both IPV introduction and the tOPV-bOPV switch were related t

53 The safely profiles of combined IPV and whole-cell pertussis vaccines, OPV and whole-cel

54 -inferior in sequential schedules containing IPV and bOPV, compared with an all-IPV schedule, and pro

55 However, current IPV delivery is less suitable for campaign use than OPV,

56 Because the current IPV is not suitable for house-to-house vaccination campa

57 been ongoing since 2014, including delaying IPV introduction in countries where risks of type 2 rein

58 ulation is a crucial milestone in developing IPV-Al.

59 assessed the immunogenicity of two different IPV-bOPV schedules compared with an all-IPV schedule in

60 tered intradermally, compared with full-dose IPV administered intramuscularly, among adults with a hi

61 ng immune responses, compared with full-dose IPV.

62 r pertussis-inactivated polio vaccine (dT5aP-IPV) was introduced in 2012.

63 in the alternating limb group received DTaP-IPV-Hib in the left leg at 2 months and in the right leg

64 lus influenzae type b combined vaccine (DTaP-IPV-Hib) at 2, 3, and 4 months of age, and the pneumococ

65 ers in Southern England immunized with DTaP5/IPV/Haemophilus influenzae b (Hib-TT) vaccine at 2-3-4 m

66 Incidence of emotional IPV did not differ (409 [20%] of 2039 vs 311 [18%] of 17

67 o-glycolic acid) (PLGA) that can encapsulate IPV along with stabilizing excipients and release immuno

68 were also used to visualize areas of excess IPV risk.

69 Incidents of heavy drinking and experiencing IPV measured over prespecified, 12 weekly assessments us

70 group on weekly assessments for experiencing IPV (odds ratio [OR], 1.02; 95% CI, 0.98-1.06) or heavy

71 For women experiencing IPV and heavy drinking, the use of a brief motivational

72 gnificant ecological risk factors explaining IPV.

73 2-dose fractional-IPV schedule could extend IPV immunization to more children.

74 ne production and an unforecasted demand for IPV use in campaigns to interrupt wild polio virus and t

75 roportionate reporting of adverse events for IPV compared with other vaccines.

76 ctiveness of a motivational intervention for IPV-involved female ED patients (ages: 18-64 years; N =

77 iance) approved the provision of support for IPV introduction in the 72 Gavi-eligible countries.

78 to provide exceptional financial support for IPV introduction to additional OPV-only using countries

79 y block-size of four, to receive one of four IPV formulations (three-times reduced dose [1/3 IPV-Al],

80 izing wastage and use of a 2-dose fractional-IPV schedule could extend IPV immunization to more child

81 , witnessing murder, and a further path from IPV led to PTSD symptoms.

82 were connected and conveyed protection from IPV.

83 irus vaccine (OPV) antibodies, and sera from IPV-immunized rats and mice.

84 ld lower neutralization titers in serum from IPV-immunized rats and mice.

85 aring strategy to stretch the limited global IPV supply while further improving population immunity.

86 However, IPV is unaffordable for many developing countries.

87 s expected in sub-Saharan Africa and Asia if IPV is offered with DTP3, rather than with DTP1.

88 nal 12 million children not receiving IPV if IPV is offered with DTP3, rather than with DTP1.

89 abilizing excipients and release immunogenic IPV over the course of several weeks.

90 We determined factors impacting IPV introduction and the value of the RI module on monit

91 ed that a one-standard-deviation increase in IPV intensity was associated with a 12.3% relative incre

92 patially structured remaining variability in IPV risk that was not explained by the covariates.

93 characteristics on small-area variations in IPV risk.

94 ve-attenuated oral (OPV) and/or inactivated (IPV) PV vaccines have systematically reduced its spread

95 Challenges among HFs included: IPV shortages (20%), hesitancy to administer 2 injectabl

96 use device to administer vaccines, including IPV.

97 ted poliovirus vaccine (fIPV) could increase IPV affordability and stretch limited supplies.

98 s the Nanopatch could facilitate inexpensive IPV vaccination in campaign settings.

99 potential tool for facilitating inexpensive IPV for mass vaccination campaigns.

100 e these efforts, there is still insufficient IPV supply to meet demand.

101 Intradermal IPV shows promise as a means to decrease the effective d

102 % of the standard dose used in intramuscular IPV, resulted in inferior antibody titers.

103 One full dose of intramuscular IPV seroconverted 33%, 41%, and 47% of infants against s

104 obal polio eradication strategy to introduce IPV into the immunisation schedules of all countries.

105 The decision to introduce IPV was based on preventing rare cases of vaccine-associ

106 n 2014 and 2016, 11 EMR countries introduced IPV in their routine immunization program, including all

107 ot use IPV by the end of 2014 had introduced IPV.

108 A total of 105 countries have introduced IPV as of September 2016 of which 85 have procured the v

109 5 of 126 countries using OPV only introduced IPV within a 2.5-year period, making it the fastest roll

110 Bangladesh successfully introduced IPV, but shortages related to insufficient global supply

111 Introducing IPV during a national multivaccination campaign led to r

112 the IPV-bOPV-bOPV, IPV-IPV-bOPV, and IPV-IPV-IPV groups, respectively, the proportions of children wi

113 the IPV-bOPV-bOPV, IPV-IPV-bOPV, and IPV-IPV-IPV groups, respectively, the proportions of children wi

114 the IPV-bOPV-bOPV, IPV-IPV-bOPV, and IPV-IPV-IPV groups, respectively, were 130 (77.4%) of 168, 95% C

115 OPV, 192 to IPV-IPV-bOPV, and 188 to IPV-IPV-IPV.

116 les: IPV-bOPV-bOPV, IPV-IPV-bOPV, or IPV-IPV-IPV.

117 tations, we found that BAG3 uses both of its IPV motifs to interact with sHsps, including Hsp27 (HspB

118 me-fixed and time-varying covariates, lagged IPV intensity had a statistically significant associatio

119 tematic review identified 13 studies linking IPV to incident depression, none of which were conducted

120 terial etiology (P = .0099) compared to male IPV recipients but equally likely to experience diarrhea

121 were reported for the more than 250 million IPV doses distributed between 2000 and 2012.

122 5) of the assessed control group reported no IPV during the previous 3 months and 19% (29 of 152) of

123 in which we expect cVDPVs in the absence of IPV use.

124 d capacity building, to ensure acceptance of IPV and continued uptake of OPV.

125 In many countries, the addition of IPV would necessitate delivery of multiple injectable va

126 data support the future co-administration of IPV, measles-rubella, and yellow fever vaccines within t

127 e on multi-dose vial policy (30%) and age of IPV administration (8%).

128 ssment approaches were used: (1) analysis of IPV vaccinations reported in NHMIS, and (2) survey of 20

129 te adjusted prevalence risk ratios (aPRR) of IPV, and adjusted incidence rate ratios (aIRR) of HIV ac

130 assess whether provision of a combination of IPV prevention and HIV services would reduce IPV and HIV

131 s to decrease the effective dose and cost of IPV, but prior studies, all using 20% of the standard do

132 results suggest that intradermal delivery of IPV may lead to dose-sparing effect and reduction of the

133 s comparable to that of the standard dose of IPV administered intramuscularly and resulted in higher

134 eeks; group 4 received bOPV plus one dose of IPV at 14 weeks; and group 5 received bOPV plus two dose

135 0 weeks, and 14 weeks and either one dose of IPV at age 14 weeks or two doses of IPV at age 14 weeks

136 ats that received 1/40th of a human dose of IPV delivered by Nanopatch, but not in rats given 1/8th

137 t in intestinal immunity following a dose of IPV given to OPV-immunized children.

138 , 74.3-85.4) infants in the bOPV-one dose of IPV group (p<0.0001 vs bOPV-only).

139 With most countries opting for one dose of IPV in routine immunisation schedules during this transi

140 e rapid introduction of at least one dose of IPV into routine immunization schedules in 126 all OPV-u

141 2:2:1 to receive 40% of the standard dose of IPV intradermally, 20% of the standard dose intradermall

142 infants) were allocated bOPV and one dose of IPV, and 22 villages (329 infants) were assigned bOPV an

143 humoral priming for type 2 from one dose of IPV.

144 immunised with bOPV and one or two doses of IPV and those who received tOPV (15 of 252 [6%] vs six o

145 and group 5 received bOPV plus two doses of IPV at 14 and 36 weeks.

146 dose of IPV at age 14 weeks or two doses of IPV at age 14 weeks and 18 weeks.

147 on of single fractional intradermal doses of IPV by needle and syringe or disposable-syringe jet inje

148 nificantly with bOPV and one or two doses of IPV compared with tOPV (17 of 751 [2%] vs three of 353 [

149 generated by fractional intradermal doses of IPV did not achieve non-inferiority compared with full d

150 Immunogenicity of fractional doses of IPV was studied by comparing intramuscular and intraderm

151 eceiving bOPV and either one or two doses of IPV, but transmission was not increased in the community

152 infants) were assigned bOPV and two doses of IPV.

153 OPV combined with zero, one, or two doses of IPV.

154 SHARE could reduce some forms of IPV towards women and overall HIV incidence, possibly th

155 ing monovalent and trivalent formulations of IPV.

156 al examined the safety and immunogenicity of IPV given alongside the measles-rubella and yellow fever

157 Effective implementation of IPV introduction and the switch from trivalent OPV (cont

158 e the days of heavy drinking or incidents of IPV.

159 the lessons learned from the introduction of IPV and the switch from tOPV to bOPV can be useful for t

160 role played by NITAGs in the introduction of IPV in the routine immunization program and the lessons

161 sing IPV except Egypt, where introduction of IPV was delayed by a global shortage.

162 The introduction of IPV was largely successful in Kano and the RI module was

163 egulatory issues before the introductions of IPV and bOPV.

164 Men reported more lifetime perpetration of IPV (physical or sexual IPV range 32.5%-80%) than women

165 omen from human rights abuses, prevention of IPV, reduction in insecurity and poverty in the post-con

166 his article is to systematize the process of IPV introduction and switch in Latin America and the Car

167 e analysed to compare the safety profiles of IPV and oral poliovirus vaccine (OPV).

168 ntions of arm B with additional provision of IPV delivered at the maternal and child health camps (ar

169 nd acceptance of the recommended schedule of IPV by the SAGE, but the evidence was largely from devel

170 en delayed because of the global shortage of IPV, making it unavailable to select lower-risk countrie

171 should be considered for better targeting of IPV prevention.

172 sional societies, thus encouraging uptake of IPV as a second or third injection in an accelerated man

173 Geocoded data on IPV cases with associated protection orders (n = 1,623)

174 The impact of the supply situation on IPV introduction timelines in countries are the focus of

175 In many ways, the IMG's work on IPV introduction can serve as a model for other vaccine

176 measures for the study were coverage of OPV, IPV, and routine extended programme on immunisation vacc

177 l], ten-times reduced dose [1/10 IPV-Al], or IPV) intramuscularly in the thigh at 6, 10, and 14 weeks

178 l schedules: IPV-bOPV-bOPV, IPV-IPV-bOPV, or IPV-IPV-IPV.

179 fIPV or IPV were administered on days 0 and 28; serum was collec

180 assigned to receive mIPV2HD (117 infants) or IPV (116 infants).

181 4 weeks after vaccination with mIPV2HD or IPV, seroconversion to poliovirus type 2 was recorded in

182 us 4 weeks after vaccination with mIPV2HD or IPV; and safety (as determined by the proportion and nat

183 ype 2 vaccine derived polio virus outbreaks, IPV supplies are severely constrained.

184 evalence rates of past-year male-perpetrated IPV and nonpartner rape from women's and men's reports a

185 erest was exposure to four types of physical IPV in the past year.

186 perience of past-year sexual and/or physical IPV: (1) poverty, (2) all childhood trauma, (3) quarrell

187 had fewer self-reports of past-year physical IPV (346 [16%] of 2127 responders in control groups vs 2

188 -IPV group (bOPV at 6, 10, and 14 weeks plus IPV at 14 weeks).

189 poliovirus (OPV) or inactivated poliovirus (IPV) vaccines and mixed schedules thereof will determine

190 We assessed conflict-related PTEs, IPV, continuing adversity (poverty and insecurity), PTSD

191 1-4 years were randomized (1:1:1) to receive IPV at 5 months (arm A), at enrollment (arm B), or no va

192 4 to receive 1/10 IPV-Al, and 206 to receive IPV.

193 vaccine, respectively, but only 65% received IPV at the same visit.

194 clustering of children who have not received IPV is expected in sub-Saharan Africa and Asia if IPV is

195 uring a single visit, with infants receiving IPV alongside pentavalent vaccine (which covers diphther

196 additional 12 million children not receiving IPV if IPV is offered with DTP3, rather than with DTP1.

197 Intensive health sector responses to reduce IPV and improve women's mental health should be explored

198 IPV prevention and HIV services would reduce IPV and HIV incidence in individuals enrolled in the Rak

199 SHARE had no effect on male-reported IPV perpetration.

200 As a result, IPV was introduced in mass campaigns to help achieve pol

201 weeks in one of three sequential schedules: IPV-bOPV-bOPV, IPV-IPV-bOPV, or IPV-IPV-IPV.

202 Separately, IPV was given as a full intramuscular or fractional intr

203 Maintaining a sequential IPV/OPV schedule instead of switching to an IPV-only sch

204 Because data are needed on sequential IPV-bOPV schedules, we assessed the immunogenicity of tw

205 ups; aPRR 0.79, 95% CI 0.67-0.92) and sexual IPV (261 [13%] of 2038 vs 167 [10%] of 1737; 0.80, 0.67-

206 ciated with past-year physical and/or sexual IPV exposure; of particular interest is the resilience p

207 s experience of past-year physical or sexual IPV from women's reports and factors driving women's pas

208 rly different from men's (physical or sexual IPV range 10.1%-34.0%).

209 han women did experience (physical or sexual IPV range 27.5%-67.4%), but women's reports of past-year

210 time perpetration of IPV (physical or sexual IPV range 32.5%-80%) than women did experience (physical

211 of past-year experience (physical or sexual IPV range 8.2%-32.1%) were not very clearly different fr

212 Adding a single IPV dose to an OPV-only routine immunization schedule at

213 Specifically, IPV was released in two separate bursts, mimicking the d

214 caused clinically relevant amounts of stable IPV release upon degradation of the PLGA matrix.

215 ular pertussis vaccines), whereas standalone IPV vaccines accounted for 0.5% of all reports.

216 A 60% reduction in the standard IPV dose without reduction in antibody titers is possibl

217 riority of three IPV-Al vaccines to standard IPV.

218 To study the association between state IPV-related firearm laws and IPH rates over a 25-year pe

219 ated paralytic polio, financially sustaining IPV introduction, ensuring equitable access to IPV, and

220 Infants of 141 TdaP5/IPV-vaccinated mothers in Southern England immunized wit

221 acellular-pertussis/inactivated-polio (TdaP5/IPV) vaccine was introduced in October 2012.

222 Results indicated that IPV risk was higher in physically disordered and decayin

223 Our most comprehensive model showed that IPV and conflict-related deprivations led directly to de

224 ical work and stakeholder consultations, the IPV Immunization Systems Management Group (IMG) presente

225 98.0% (P = 1.00), and 99.2% (P = .45) in the IPV arm.

226 86 (74.8%, 65.8-82.4) of 115 infants in the IPV group (difference between groups 18.3%, 95% CI 5.0-3

227 the mIPV2HD group and 36 (18.0-113.8) in the IPV group (difference between groups 98.8, 95% CI 60.7-1

228 D group and seven (6%) of 116 infants in the IPV group during the 8-week period after vaccination; no

229 n seroconverting to type 2 poliovirus in the IPV-bOPV-bOPV, IPV-IPV-bOPV, and IPV-IPV-IPV groups, res

230 In the IPV-bOPV-bOPV, IPV-IPV-bOPV, and IPV-IPV-IPV groups, res

231 In the IPV-bOPV-bOPV, IPV-IPV-bOPV, and IPV-IPV-IPV groups, res

232 formulations, 1.4, 1.1, and 1.2 doses of the IPV serotype 1, 2, and 3, respectively, were released wi

233 accine were randomly assigned to receive the IPV, measles-rubella, and yellow fever vaccines, singula

234 ticle, and based on lessons learned with the IPV introductions, it is recommended for future health p

235 of type 2 faecal shedding compared with the IPV-only schedule.

236 ial was to show the non-inferiority of three IPV-Al vaccines to standard IPV.

237 s 1, 2, and 3 was already high for the three IPV-Al vaccines after two vaccinations, but was higher a

238 V-bOPV-bOPV, 192 to IPV-IPV-bOPV, and 188 to IPV-IPV-IPV.

239 we assigned 570 infants to treatment: 190 to IPV-bOPV-bOPV, 192 to IPV-IPV-bOPV, and 188 to IPV-IPV-I

240 s to treatment: 190 to IPV-bOPV-bOPV, 192 to IPV-IPV-bOPV, and 188 to IPV-IPV-IPV.

241 Alliance, UNICEF set out to secure access to IPV supply for around 100 countries.

242 V introduction, ensuring equitable access to IPV, and preparing for future OPV cessation following gl

243 oral poliovirus vaccine (OPV) in addition to IPV.

244 des, social norms, and behaviours related to IPV, and a screening and brief intervention to promote s

245 State laws that prohibit persons subject to IPV-related restraining orders from possessing firearms

246 As countries transition to IPV in immunization schedules, they may need to actively

247 ed, 3-y cluster-randomized controlled trial, IPV had a statistically significant association with dep

248 dose of either mIPV2HD or standard trivalent IPV given concurrently with a third dose of bOPV at 14 w

249 After a bOPV-two IPV schedule, all 193 infants (100%, 98.0-100; p<0.0001

250 After one or two IPV doses in addition to bOPV, 80% and 100% of infants s

251 In the USA, IPV has been included in the routine immunisation schedu

252 5 of 17 countries and areas that did not use IPV by the end of 2014 had introduced IPV.

253 the end of 2016 all EMR countries were using IPV except Egypt, where introduction of IPV was delayed

254 (1:1:1) to receive three polio vaccinations (IPV by injection or bOPV as oral drops) at age 8, 16, an

255 tOPV (n = 315) or inactivated polio vaccine (IPV) (n = 299) at 39 weeks.

256 troduction of the inactivated polio vaccine (IPV) and the switch from trivalent oral polio vaccine (t

257 a have introduced inactivated polio vaccine (IPV) as part of the Global Polio Eradication and Endgame

258 e introduction of inactivated polio vaccine (IPV) in combination with OPV.

259 orts to introduce inactivated polio vaccine (IPV) into all countries that did not yet include it in t

260 lbania introduced inactivated polio vaccine (IPV) into its immunization system in May 2014, increasin

261 geria, introduced inactivated polio vaccine (IPV) into its routine immunization (RI) schedule in Marc

262 t least 1 dose of Inactivated Polio Vaccine (IPV) into routine immunization schedules by the end of 2

263 t least 1 dose of inactivated polio vaccine (IPV) into the routine immunization programs of all count

264 t least 1 dose of inactivated polio vaccine (IPV) into their routine immunization schedules by the en

265 Inactivated polio vaccine (IPV) is necessary for global polio eradication because o

266 ) and one dose of inactivated polio vaccine (IPV) where available.

267 sets, introducing inactivated polio vaccine (IPV), and replacing trivalent oral polio vaccine with bi

268 es, including the inactivated polio vaccine (IPV), must be injected more than once for efficacy.

269 exclusively with inactivated polio vaccine (IPV).

270 ges in the use of inactivated polio vaccine (IPV).

271 1 dose of inactivated poliomyelitis vaccine (IPV); withdraw oral poliomyelitis vaccine (OPV), startin

272 s' uptake of inactivated poliovirus vaccine (IPV) after its introduction into the routine immunizatio

273 n the use of inactivated poliovirus vaccine (IPV) are important for the global polio eradication stra

274 roduction of inactivated poliovirus vaccine (IPV) are major steps in the polio endgame strategy.

275 showed that inactivated poliovirus vaccine (IPV) boosts intestinal immunity in children previously i

276 nal doses of inactivated poliovirus vaccine (IPV) delivered intradermally to induce levels of serum p

277 Inactivated poliovirus vaccine (IPV) does not induce an intestinal mucosal immune respon

278 one dose of inactivated poliovirus vaccine (IPV) in routine immunisation programmes to eliminate vac

279 introducing inactivated poliovirus vaccine (IPV) into routine vaccination programs.

280 e-affordable inactivated poliovirus vaccine (IPV) options for low-income countries.

281 ction of the inactivated poliovirus vaccine (IPV) represents a crucial step in the polio eradication

282 ge with only inactivated poliovirus vaccine (IPV) since 2005.

283 ole of using inactivated poliovirus vaccine (IPV) to manage the risks of circulating vaccine-derived

284 PV) in 2016, inactivated poliovirus vaccine (IPV) will be the only source of protection against polio

285 placed with inactivated poliovirus vaccines (IPV).

286 Intimate partner violence (IPV) and heavy drinking are co-occurring public health p

287 male-perpetrated intimate partner violence (IPV) and risk factors is essential for building evidence

288 Intimate partner violence (IPV) is associated with HIV infection.

289 ogical impacts of intimate partner violence (IPV) is derived primarily from studies conducted in high

290 arm possession by intimate partner violence (IPV) offenders.

291 ng these factors, intimate partner violence (IPV), and continuing adversity in women in Timor-Leste.

292 ns in the risk of intimate partner violence (IPV).

293 We analysed all VAERS data associated with IPV submitted between Jan 1, 2000, and Dec 31, 2012, eit

294 ng of adverse events after immunisation with IPV-containing vaccines compared with other vaccines bet

295 No problems with IPV storage, transport, or waste disposal were detected,

296 Among 73 infants not vaccinated with IPV, 58% of caregivers reported that vaccine was unavail

297 Mexican community primarily vaccinated with IPV.

298 (97%) were for simultaneous vaccination with IPV and other vaccines (most commonly pneumococcal and a

299 ted experience and perpetration of past year IPV (emotional, physical, and sexual) and laboratory-bas

300 Past-year IPV indicators based on women's reported experience that